Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne

被引:0
|
作者
Del Rosso, James [1 ,2 ,3 ]
Gold, Linda Stein [4 ]
Tyring, Stephen [5 ]
Zeichner, Joshua [6 ]
Callender, Valerie [7 ,8 ]
Draelos, Zoe [9 ]
Werschler, William [10 ]
Cook-Bolden, Fran [11 ]
Guenin, Eric [12 ]
机构
[1] JDR Dermatol Res Thomas Dermatol, Las Vegas, NV 89149 USA
[2] Adv Dermatol & Cosmet Surg, Maitland, FL 32751 USA
[3] Tour Univ Nevada, Henderson, NV 89014 USA
[4] Henry Ford Hosp, Detroit, MI 48202 USA
[5] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Callender Dermatol & Cosmet Ctr, Glenn Dale, MD USA
[8] Howard Univ, Coll Med, Washington, DC USA
[9] Dermatol Consulting Serv PLLC, High Point, NC USA
[10] Univ Washington, Sch Med, Seattle, WA USA
[11] Weill Cornell, Dept Dermatol, New York, NY USA
[12] Ortho Dermatol, Bridgewater, NJ USA
关键词
QUALITY-OF-LIFE; TOPICAL RETINOIDS; DOUBLE-BLIND; VULGARIS; MULTICENTER; ADAPALENE; SKIN;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: While topical retinoids are a mainstay of acne treatment, acne can manifest differently in various skin types. The objective of these post hoc analyses from two pooled phase 3 studies was to examine efficacy and safety of tazarotene 0.045% and quality of life improvements in self-identified Caucasian adults with moderate-to-severe acne. Methods: In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321), participants aged >= 9 years with moderateto-severe acne were randomized (1:1) to tazarotene 0.045% lotion or vehicle lotion (N=1,614); a subset of adults (>= 18 years) who selfreported Caucasian (White) race (n=645) were examined. Coprimary endpoints were inflammatory/noninflammatory lesion counts and treatment (endpoint) success (>= 2-grade reduction from baseline in Evaluator's Global Severity Score and a score of 0 [clear] or 1 [almost clear]). Quality of life, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability were also assessed. Results: At week 12, tazarotene lotion significantly reduced lesion counts by 60% (least-squares mean percent changes from baseline, tazarotene vs vehicle: inflammatory, -61.2% vs -51.1%; noninflammatory, -59.7% vs -49.3%; P<0.001, both). Significantly more participants achieved treatment success with tazarotene lotion versus vehicle (P<0.001). Numerical improvements in qualityof-life domains were observed from baseline to week 12. Most TEAEs were unrelated to treatment, and rates of moderate-to-severe erythema decreased from baseline to week 12 with tazarotene treatment. Conclusions: Tazarotene 0.045% lotion was efficacious and well tolerated over 12 weeks and led to quality-of-life improvements in Caucasian adults with moderate-to-severe acne. These results, along with those from patients with skin of color, demonstrate that once daily tazarotene 0.045% lotion is an effective and well-tolerated treatment option regardless of race or skin color.
引用
收藏
页码:1061 / 1069
页数:9
相关论文
共 50 条
  • [41] Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study
    Chen, Baili
    Zhong, Jie
    Li, Xiuling
    Pan, Feng
    Ding, Yijuan
    Zhang, Yan
    Chen, Hong
    Liu, Fei
    Zhang, Zhenyu
    Zhang, Ling
    Drozda, Rafal
    Oliinyk, Oleksandr
    Goh, Aik Han
    Chen, Xiang
    Sun, Xiang
    Rubin, David T.
    Sandborn, William J.
    Chen, Minhu
    GASTROENTEROLOGY, 2022, 163 (06) : 1555 - 1568
  • [42] Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
    Papp, Kim
    Menter, Alan
    Strober, Bruce
    Kricorian, Greg
    Thompson, ElizabethH. Z.
    Milmont, Cassandra E.
    Nirula, Ajay
    Klekotka, Paul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (03) : 436 - U100
  • [43] Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis
    Zheng, Hui
    Chen, Yan
    Xu, Yunsheng
    Deng, Xinjie
    EUROPEAN JOURNAL OF DERMATOLOGY, 2023, 33 (05) : 530 - 543
  • [44] Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis
    Golhen, Klervi
    Winskill, Carolyn
    Theiler, Martin
    Buettcher, Michael
    Yeh, Yu-Hsin
    Zhang, Nancy
    Welzel, Tatjana
    Pfister, Marc
    FRONTIERS IN MEDICINE, 2022, 9
  • [45] Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review
    Roekevisch, Evelien
    Spuls, Phyllis Ira
    Kuester, Denise
    Limpens, Jacqueline
    Schmitt, Jochen
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : 429 - 438
  • [46] Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
    Huang, Yuanjie
    Cai, Limin
    Wu, Xuerui
    Chen, Chen
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2023, 40 (06): : 725 - 733
  • [47] Safety and Effectiveness of Microfocused Ultrasound With Visualization for the Correction of Moderate to Severe Atrophic Acne Scars
    Maas, Corey S.
    Joseph, John H.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (11) : 1109 - 1114
  • [48] Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
    Schmitt, J.
    Rosumeck, S.
    Thomaschewski, G.
    Sporbeck, B.
    Haufe, E.
    Nast, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) : 274 - 303
  • [49] Treatments for Moderate-to-Severe Acne Vulgaris: A Systematic Review and Network Meta-Analysis
    Harper, Julie C.
    Baldwin, Hilary
    Choudhury, Saswata Paul
    Rai, Deepti
    Ghosh, Bikramaditya
    Aman, Md Sohail
    Choudhury, Abhra R.
    Dutta, Sekhar Kumar
    Dey, Debalina
    Bhattacharyya, Subrata
    Lin, Tina
    Joseph, George
    Dashputre, Ankur A.
    Tan, Jerry K. L.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2024, 23 (04) : 216 - 226
  • [50] Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females
    Harper, Julie C.
    Baldwin, Hilary
    Gold, Linda Stein
    Guenin, Eric
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (11) : 1147 - 1154